|
Handbook of Nuclear Medicine and Molecular Imaging for Physicists |
|
|
|
Instrumentation and Imaging Procedures, Volume I |
|
|
Preface |
|
ix | |
Editor |
|
xi | |
Contributors |
|
xii | |
|
Chapter 1 The History of Nuclear Medicine |
|
|
1 | (14) |
|
|
Chapter 2 Basic Atomic and Nuclear Physics |
|
|
15 | (24) |
|
|
|
Chapter 3 Basics of Radiation Interactions in Matter |
|
|
39 | (30) |
|
|
Chapter 4 Radionuclide Production |
|
|
69 | (20) |
|
|
|
89 | (18) |
|
|
Chapter 6 Scintillation Detectors |
|
|
107 | (22) |
|
|
Chapter 7 Semiconductor Detectors |
|
|
129 | (16) |
|
|
Chapter 8 Gamma Spectrometry |
|
|
145 | (30) |
|
|
Chapter 9 Properties of the Digital Image |
|
|
175 | (22) |
|
Katarina Sjbgreen Gleisner |
|
|
Chapter 10 Image Processing |
|
|
197 | (24) |
|
|
Chapter 11 Machine Learning |
|
|
221 | (16) |
|
|
Chapter 12 Image File Structures in Nuclear Medicine |
|
|
237 | (14) |
|
|
Chapter 13 The Scintillation Camera |
|
|
251 | (14) |
|
|
Chapter 14 Collimators for Gamma Ray Imaging |
|
|
265 | (14) |
|
|
Chapter 15 Image Acquisition Protocols |
|
|
279 | (18) |
|
|
Chapter 16 Single Photon Emission Computed Tomography (SPECT) and SPECT/CT Hybrid Imaging |
|
|
297 | (18) |
|
|
|
Chapter 17 Dedicated Tomographic Single Photon Systems |
|
|
315 | (18) |
|
|
|
|
333 | (10) |
|
|
Chapter 19 Dead-time Effects in Nuclear Medicine Imaging Studies |
|
|
343 | (12) |
|
|
|
Chapter 20 Principles of Iterative Reconstruction for Emission Tomography |
|
|
355 | (34) |
|
|
Chapter 21 PET-CT Systems |
|
|
389 | (8) |
|
|
Chapter 22 Clinical Molecular PET/MRI Hybrid Imaging |
|
|
397 | (30) |
|
|
Chapter 23 Quality Assurance of Nuclear Medicine Systems |
|
|
427 | (28) |
|
|
Chapter 24 Calibration and Traceability |
|
|
455 | (8) |
|
|
Chapter 25 Activity Quantification from Planar Images |
|
|
463 | (16) |
|
Katarina Sjogreen Gleisner |
|
|
Chapter 26 Quantification in Emission Tomography |
|
|
479 | (20) |
|
|
|
|
Chapter 27 Multicentre Studies: Hardware and Software Requirements |
|
|
499 | (16) |
|
|
|
|
|
Chapter 28 Preclinical Molecular Imaging Systems |
|
|
515 | (18) |
|
|
Chapter 29 Monte Carlo Simulation of Nuclear Medicine Imaging Systems |
|
|
533 | (30) |
|
|
|
Chapter 30 Beta and Alpha Particle Autoradiography |
|
|
563 | (26) |
|
|
|
|
Chapter 31 Principles behind Computed Tomography (CT) |
|
|
589 | (16) |
|
|
|
Chapter 32 Principles behind Magnetic Resonance Imaging (MRI) |
|
|
605 | |
|
|
Handbook of Nuclear Medicine and Molecular Imaging for Physicists |
|
|
|
Modelling, Dosimetry, and Radiation Protection, Volume II |
|
|
Preface |
|
vii | |
Editor |
|
ix | |
Contributors |
|
xi | |
|
Chapter 1 Introduction to Biostatistics |
|
|
1 | (16) |
|
|
|
|
17 | (16) |
|
|
|
Chapter 3 Diagnostic Dosimetry |
|
|
33 | (36) |
|
|
|
Chapter 4 Time-activity Curves: Data, Models, Curve Fitting, and Model Selection |
|
|
69 | (14) |
|
|
Chapter 5 Tracer Kinetic Modelling and Its Use in PET Quantification |
|
|
83 | (18) |
|
|
|
Chapter 6 Principles of Radiological Protection in Healthcare |
|
|
101 | (14) |
|
|
Chapter 7 Controversies in Nuclear Medicine Dosimetry |
|
|
115 | (8) |
|
|
Chapter 8 Monte Carlo Simulation of Photon and Electron Transport in Matter |
|
|
123 | (18) |
|
|
Chapter 9 Patient Models for Dosimetry Applications |
|
|
141 | (14) |
|
|
Chapter 10 Patient-specific Dosimetry Calculations |
|
|
155 | (14) |
|
|
|
|
|
Chapter 11 Whole-body Dosimetry |
|
|
169 | (14) |
|
|
Chapter 12 Personalized Dosimetry in Radioembolization |
|
|
183 | (24) |
|
|
|
Chapter 13 Thyroid Imaging and Dosimetry |
|
|
207 | (16) |
|
|
|
Chapter 14 Bone Marrow Dosimetry |
|
|
223 | (12) |
|
|
Chapter 15 Cellular and Multicellular Dosimetry |
|
|
235 | (32) |
|
|
Chapter 16 Alpha-particle Dosimetry |
|
|
267 | (8) |
|
|
Chapter 17 Staff Radiation Protection |
|
|
275 | (18) |
|
|
Chapter 18 IAEA Support to Nuclear Medicine |
|
|
293 | |
|
|
Handbook of Nuclear Medicine and Molecular Imaging for Physicists |
|
|
|
Radiopharmaceuticals and Clinical Applications, Volume III |
|
|
Preface |
|
ix | |
Editor |
|
xi | |
Contributors |
|
xiii | |
|
Chapter 1 Principles behind Radiopharmacy |
|
|
1 | (12) |
|
|
|
Chapter 2 Radiopharmaceuticals for Diagnostics: Planar/SPECT |
|
|
13 | (14) |
|
|
|
Chapter 3 Radiopharmaceuticals for Diagnostics: PET |
|
|
27 | (12) |
|
|
Chapter 4 Radiopharmaceuticals for Radionuclide Therapy |
|
|
39 | (16) |
|
|
|
|
|
Chapter 5 Design Considerations for a Radiopharmaceutical Production Facility |
|
|
55 | (4) |
|
|
Chapter 6 Methods and Equipment for Quality Control of Radiopharmaceuticals |
|
|
59 | (12) |
|
|
|
|
|
|
Chapter 7 Environmental Compliance and Control for Radiopharmaceutical Production: Commercial Manufacturing and Extemporaneous Preparation |
|
|
71 | (16) |
|
|
|
|
|
Chapter 8 GMP: Rules and Recommendations |
|
|
87 | (8) |
|
|
Chapter 9 Management of Radioactive Waste in Nuclear Medicine |
|
|
95 | (6) |
|
|
|
Chapter 10 Translation of Radiopharmaceuticals: Mouse to Man |
|
|
101 | (16) |
|
|
|
|
|
|
Chapter 11 Radionuclide Bone Scintigraphy |
|
|
117 | (22) |
|
|
|
Chapter 12 Radionuclide Examination of the Kidneys |
|
|
139 | (34) |
|
|
|
Chapter 13 Neuroimaging in Nuclear Medicine |
|
|
173 | (16) |
|
|
|
Chapter 14 Methodology and Clinical Implementation of Ventilation/Perfusion Tomography for Diagnosis and Follow-up of Pulmonary Embolism and Other Pulmonary Diseases: Clinical Use of Hybrid V/P SPECT-CT |
|
|
189 | (12) |
|
|
|
Chapter 15 Myocardial Perfusion Imaging |
|
|
201 | (12) |
|
|
|
|
Chapter 16 Infection and Inflammation |
|
|
213 | (18) |
|
|
Andor W. J. M. Glaudemans |
|
|
Chapter 17 Special Considerations in Pediatric Nuclear Medicine |
|
|
231 | (12) |
|
|
|
|
|
Chapter 18 Antibody-based Radionuclide Imaging |
|
|
243 | (12) |
|
|
|
|
Chapter 19 Radionuclide-based Diagnosis and Therapy of Prostate Cancer |
|
|
255 | (50) |
|
|
|
|
|
Chapter 20 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours |
|
|
305 | (8) |
|
|
Katarina Sjogreen Gleisner |
|
|
Chapter 21 Lymphoscintigraphy |
|
|
313 | (12) |
|
|
|
|
Chapter 22 Diagnostic Ultrasound |
|
|
325 | (12) |
|
|
Chapter 23 Clinical Trials: Purpose and Procedures |
|
|
337 | (8) |
|
|
Chapter 24 Introduction to Patient Safety and Improvement Knowledge |
|
|
345 | (12) |
|
|
Chapter 25 Closing Remarks |
|
|
357 | |
|